Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Tumor Mapping in Resectable Pancreatic Cancer
NCT03718650Phase 1Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pimonidazole in pancreatic ductal adenocarcinoma (PDAC), sponsored by Moffitt Cancer Center. Primary endpoint: Radiosensitivity Index and Degree of Pimonidazole Staining up to 14 weeks. Planned start Apr 2021; status: withdrawn.
02
Drugs
pimonidazole
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03718650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718650.